Lv4
702 积分 2025-07-13 加入
Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma
29天前
已关闭
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
29天前
已完结
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
29天前
已完结
Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature
1个月前
已完结
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
1个月前
已完结
Preformulation evaluation of selumetinib for topical application: skin distribution and photodegradation analysis using MALDI imaging and LC-MS/MS
1个月前
已完结
Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors: A Retrospective Single-Center Study
1个月前
已关闭
Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
1个月前
已完结
Visual Improvement in a Child With Periorbital Plexiform Neurofibroma Treated With Selumetinib: Case Report and Literature Review
1个月前
已完结
Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib
1个月前
已关闭
皖公网安备34019202002308
